Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond
Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, Kamenov ZA, Bevilacqua A, Carlomagno G, Gerli S, Oliva MM, Devroey P
Published in Expert Opinion on Drug Metabolism and Toxicology
Methodology
Expert consensus review synthesising clinical evidence and mechanistic data on myo-inositol and D-chiro-inositol dosing, ratios and safety in PCOS and insulin resistance.
Key Findings
The 40:1 myo-inositol to D-chiro-inositol ratio reflects physiological plasma proportions and is recommended for restoring ovulation and insulin sensitivity, with high-dose D-chiro-inositol potentially detrimental to oocyte quality.
Conclusions
Dose and isomer ratio matter substantially when using inositol in PCOS.
Limitations
Consensus opinion rather than a systematic review; several authors have industry relationships.
Supplements Studied
The 40:1 myo-inositol to D-chiro-inositol ratio is recommended for restoring ovulation and insulin sensitivity.
The 40:1 myo-inositol to D-chiro-inositol ratio reflects physiological plasma proportions and is recommended for restoring ovulation and insulin sensitivity, with high-dose D-chiro-inositol potentially detrimental to oocyte quality.
Outcomes Measured
The 40:1 myo-inositol to D-chiro-inositol ratio reflects physiological plasma proportions and is recommended for restoring ovulation and insulin sensitivity, with high-dose D-chiro-inositol potentially detrimental to oocyte quality.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Expert panel with industry-affiliated authors
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.